Innoviva Inc (INVA)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 179 722 | 49 877 | 233 354 | 233 013 | 213 921 | 292 580 | 99 495 | 187 504 |
| Aktywa razem | w tys. USD | 1 243 510 | 1 188 100 | 1 118 240 | 1 129 770 | 1 231 500 | 1 327 710 | 1 137 640 | 1 107 470 |
| ROA | 14,45% | 4,20% | 20,87% | 20,62% | 17,37% | 22,04% | 8,75% | 16,93% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $179 722K ÷ $1 243 510K
= 14,45%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Innoviva Inc
INVA
14,45%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Collegium Pharmaceutical Inc
COLL
4,21%
Dynavax Technologies Corp.
DVAX
-0,64%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Medifast Inc
MED
32,08%
Myriad Genetics, Inc.
MYGN
-22,97%
Xencor Inc
XNCR
-13,23%